Compare Millicom International Cellular S.A. Common Stock (TIGO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Millicom International Cellular S.A. Common Stock vs TransMedics Group Inc — how do they compare? Millicom International Cellular S.A. Common Stock trades at $80.27 (market cap $13.34B), while TransMedics Group Inc trades at $75.46 (market cap $2.74B). The key difference: Millicom International Cellular S.A. Common Stock is far larger — about 4.9× TransMedics Group Inc's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.77% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Millicom International Cellular S.A. Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| TIGO | TMDX | |
|---|---|---|
Market Cap | $13.34B | $2.74B |
Volume | 1,586,684 | 1,025,926 |
Sector | Media | Health |
52-Week High | $104.31 | $150.42 |
52-Week Low | $45.81 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $24.38B | $3.14B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
TMDX trades at $79.14, up 1.23% on the day, but faces a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Recent news highlights insider buying and a new CFO appointment, alongside multiple legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but near-term risks include earnings volatility, legal scrutiny, and a declining net cash flow trend. Investors should weigh solid fundamentals against execution and sentiment risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
